ストックスクリーナーアプリを入手
8.91
1.71%
0.15
アフターアワーズ：
8.89
-0.02
-0.22%
Ocular Therapeutix Inc (OCUL) 最新ニュース
Ocular Therapeutix (OCUL) soars 10.4% ahead of business updates - MSN
Discipline and Rules-Based Execution in OCUL Response - Stock Traders Daily
Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study - Sahm
H.C. Wainwright reiterates Ocular Therapeutix stock rating on trial data By Investing.com - Investing.com Canada
New Ocular SVP gets 300,000 stock options in inducement grant - Stock Titan
Here is why Ocular Therapeutix (OCUL) is highly favored by hedge funds - MSN
Aug EndMonth: Can Ocular Therapeutix Inc maintain its current growth rateWeekly Gains Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Large Ocular Therapeutix (OCUL) share gift to spouse disclosed - Stock Titan
William Blair reiterates Ocular Therapeutix stock rating on trial data By Investing.com - Investing.com Canada
Ocular Therapeutix Inc Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD - marketscreener.com
Ocular Therapeutix presents additional wet AMD trial data By Investing.com - Investing.com Australia
William Blair Maintains Ocular Therapeutix(OCUL.US) With Buy Rating - Moomoo
OCUL Reiterates by HC Wainwright & Co. -- Price Target Maintained at $21 - GuruFocus
What's Going On With Ocular Therapeutix Stock Monday?Ocular Therapeutix (NASDAQ:OCUL) - Benzinga
Positive Week 52 Data Released for Ocular Therapeutix (OCUL) - GuruFocus
Is Ocular Therapeutix (OCUL) Quietly Recasting Its Retinal Strategy Around Axpaxli’s Phase 3 Design Choices? - Yahoo Finance
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD - The Manila Times
Ocular Therapeutix Presents New SOL-1 Data Reinforcing AXPAXLI's Efficacy and Durability in Wet AMD at VBS Meeting - Quiver Quantitative
Ocular Therapeutix presents additional wet AMD trial data - Investing.com
Ocular Therapeutix™ Announces Additional Positive Week 52 - GlobeNewswire
Assessing Whether Ocular Therapeutix (OCUL) Looks Undervalued After Recent Mixed Share Price Performance - Yahoo Finance
Sectors Review: Is Ocular Therapeutix Inc undervalued by DCF analysis2026 Drop Watch & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Aug Rallies: Should I invest in Ocular Therapeutix Inc before earnings2026 Pullbacks & Safe Entry Zone Tips - baoquankhu1.vn
Ocular Therapeutix Stock Surges 10% Past $9 on Fresh SOL-1 Data Presentations for AXPAXLI - International Business Times Australia
Ocular Therapeutix (OCUL) Soars 10.4% Ahead of Business Updates - Insider Monkey
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - MSN
Market Leaders: Will Ocular Therapeutix Inc stock hit new highs in YEAR - baoquankhu1.vn
Update Recap: Will Ocular Therapeutix Inc benefit from geopolitical trendsTrade Signal Summary & Verified Momentum Stock Alerts - baoquankhu1.vn
Will Ocular Therapeutix’s (OCUL) AXPAXLI Data Spotlight Redefine Its Retinal Competitive Positioning? - Sahm
Behavioral Patterns of OCUL and Institutional Flows - Stock Traders Daily
OCULAR THERAPEUTIX, INC. (OCUL) - MSN
HC Wainwright lifts Ocular Therapeutix, Inc. (OCUL) price target following intravitreal implant FDA submission - MSN
OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April - Sahm
Analysis Recap: How sensitive is Ocular Therapeutix Inc to inflation2026 Analyst Calls & Daily Technical Stock Forecast Reports - baoquankhu1.vn
OCUL Earning Date, Earning Analysis and Earning Prediction - intellectia.ai
Here is Why Ocular Therapeutix (OCUL) is Highly Favored by Hedge Funds - Insider Monkey
Ocular Therapeutix to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April - Bitget
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 9.3%Should You Buy? - marketbeat.com
OCULAR THERAPEUTIX (01477.HK) Completes First Patient Enrollment in Phase III Clinical Trial for OT-211 - AASTOCKS.com
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Short Interest Up 34.2% in March - MarketBeat
Assenagon Asset Management S.A. Has $7.54 Million Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Why Ocular Therapeutix (OCUL) Is Down 7.7% After Single‑Trial FDA Plan For AXPAXLI Superiority Claim - Sahm
What Ocular Therapeutix (OCUL)'s Single-Study FDA Bid After SOL-1 Superiority Means For Shareholders - Yahoo Finance
Vanguard reports zero holdings in Ocular Therapeutix (OCUL) - Stock Titan
H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy - Investing.com
H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy By Investing.com - Investing.com UK
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Ocular Therapeutix, Inc. (OCUL): A bull case theory - MSN
Ocular Therapeutix Touts Landmark Phase 3 AXPAXLI Win at RBC Ophthalmology Conference - marketbeat.com
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):